




















 



 Angiotech Pharmaceuticals Completes Sale to Investor Syndicate Led by Vivo Capital and ZQ Capital 
         










    










 













 











 



















Angiotech Pharmaceuticals Completes Sale to Investor Syndicate Led by Vivo Capital and ZQ Capital
        																																
              











 News provided by
Vivo Capital  
Mar 21, 2017, 06:00 ET









 Share this article




























































PALO ALTO, Calif. and VANCOUVER, British Columbia, March 21, 2017 /PRNewswire/ -- Angiotech Pharmaceuticals, a leading medical device company focused on high value medical consumables in the wound closure and ophthalmology sectors, today announced the completion of its sale to a group of investors led by Vivo Capital LLC and ZQ Capital Limited.  The investment syndicate also includes GSO Capital Partners LP, China Orient Asset Management (International) Holding Limited, Fung Shing Investments Ltd, ZZ Capital Co., Ltd, ABCI Investment Management Limited, Cathay Venture Inc. and Nan Fung Group.  In addition, business development companies managed by affiliates of FS Investments and sub-advised by an affiliate of GSO Capital Partners LP (GSO, a division of The Blackstone Group), ABCI Investment Management Limited, and China Minsheng Banking Corporation Limited, Hong Kong Branch, provided senior secured financing for the transaction.  The terms of the transaction were not disclosed.  








Angiotech is a leading diversified medical device manufacturer of branded, private label and OEM products.  The company has more than 2,000 employees worldwide, has manufacturing facilities in England, Puerto Rico, Mexico and Germany, and sells to customers in over 80 countries.  
O'Melveny & Myers LLP was legal advisor to the investment syndicate and Paul Hastings LLP and Magstone Law were legal advisors to ZQ Capital. Piper Jaffray & Co was financial advisor and Irell & Manella LLP served as legal advisor, respectively, to Angiotech.
About Vivo Capital
Vivo Capital is a global healthcare focused investment firm formed in 1996 with over $1.8 billion under management.  Vivo Capital has offices in Palo Alto, California, Beijing, Shanghai and Taipei.  Vivo's current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
More information can be found at www.vivocapital.com.
About ZQ Capital Limited
ZQ Capital is an investment firm headquartered in Hong Kong.  The firm specializes in identifying, investing in, and partnering with global companies to realize their growth potential in the Chinese market by levering ZQ Capital's deep local knowledge of China as well as extensive relationships with financial institutions and leading entrepreneurs throughout Asia.
About China Orient Asset Management (International) Holding Limited
China Orient Asset Management (International) Holding Limited ("COAMI") is headquartered in Hong Kong, and is a wholly-owned subsidiary and primary overseas platform of China Orient Asset Management Co. Ltd.  As of 31 December 2015, COAMI has assets over HKD 52bn. The key businesses of COAMI include investment, corporate finance advisory, non-performing asset acquisitions and asset management.
About Fung Shing Investment Limited
Fung Shing Investment Limited is an investment company. With extensive experience and knowledge, Fung Shing invests in various sectors, including but not limited to media, telecom, healthcare, real estates and financial institutions.
About ZZ Capital Co., Ltd
ZZ Capital Co., Ltd ("ZZ Capital") is a global investment firm headquartered in Beijing and an affiliate of Zhongzhi Group, a leading financial services company with more than US$240bn AUM across a variety of investment and wealth management platforms. ZZ Capital and its affiliate, ZZ Capital International (a Hong Kong listed company), are the global flagship private equity investment vehicles for the Zhongzhi Group. ZZ Capital seeks buyout and investment opportunities in the healthcare, financial services, TMT, education, media and advanced manufacturing sectors to create true partnerships, drive value enhancement and leverage its unique positioning in China. The business operates offices in Beijing, Hong Kong, New York, San Francisco, London and Tel Aviv.
About Cathay Venture Inc.
Cathay Venture is an evergreen fund wholly-owned by Cathay Financial Holding, based in Taipei, Taiwan. Cathay Financial Group establishes its presence in Taiwan on December 31, 2001, with registered capital of NTD$120 Billion. Composed of insurance, securities, banking and other diversified financial institutions, Cathay Financial Holdings is a full-functioning financial platform.
About Nan Fung Group
Founded in 1954, Nan Fung Group is a fully integrated, multi-disciplinary conglomerate based in Hong Kong with global interests in real estate development and investment, financial investment, hotels and shipping.
About China Minsheng Banking Corporation Limited, Hong Kong Branch
Opened on 30 March 2012, China Minsheng Banking Corporation Limited, Hong Kong Branch ("CMBC HK") is the first and only overseas branch of China Minsheng Banking Corp., Ltd.  CMBC HK has been active in providing offshore transaction based financing to its PE or corporate clients.
About Angiotech 
Angiotech Pharmaceuticals  has developed and manufactured branded, private label, and OEM surgical instruments for over 40 years. The Company offers one of the most comprehensive portfolios of blades and sutures available, including innovative products such as the Quill Knotless Tissue-Closure Device. Headquartered in Vancouver, CA, Angiotech devotes itself to exceeding the needs of the specialty surgery market, having trusted partnerships within dental, ophthalmic, plastic surgery, dermatology, orthopedics, urology, microsurgery, veterinary and trauma specialties. The key shareholders in Angiotech include affiliates of Blue Mountain Capital LLC, Courage Capital Management LLC and Cetus Capital LLC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/angiotech-pharmaceuticals-completes-sale-to-investor-syndicate-led-by-vivo-capital-and-zq-capital-300426505.html
SOURCE Vivo Capital
 Related Links

http://vivocapital.com/



 













Dec 19, 2016, 06:00 ET
Preview: Vivo Capital and ZQ Capital Limited enter into an Agreement to Acquire Angiotech Pharmaceuticals






My News


  Release contains wide tables.	  View fullscreen.





 You just read:
Angiotech Pharmaceuticals Completes Sale to Investor Syndicate Led by Vivo Capital and ZQ Capital


 News provided by
Vivo Capital  
Mar 21, 2017, 06:00 ET








 Share this article









































 











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

















Search











Searching for your content...









Advanced Search












































 




Vivo Capital, LLC: Private Company Information - Bloomberg









































  





















































































July 29, 2017 12:48 AM ET
Capital Markets

Company Overview of Vivo Capital, LLC



Snapshot People




Company Overview
Vivo Capital, LLC is a private equity and venture capital firm specializing in incubation, seed, startup, mezzanine, and PIPE investments in private and public companies. The firm seeks to invest in all financing stages from Series A to public companies. It primarily invests in healthcare, biotechnology, and life science companies. The firm also seeks to invest in companies with later-stage therapeutic products in clinical development. It typically makes investments in United States and Asia Pacific based companies with a focus on later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo Capital, LLC was f...
Vivo Capital, LLC is a private equity and venture capital firm specializing in incubation, seed, startup, mezzanine, and PIPE investments in private and public companies. The firm seeks to invest in all financing stages from Series A to public companies. It primarily invests in healthcare, biotechnology, and life science companies. The firm also seeks to invest in companies with later-stage therapeutic products in clinical development. It typically makes investments in United States and Asia Pacific based companies with a focus on later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo Capital, LLC was founded in 1996 and is based in Palo Alto, California with additional offices in Beijing, China; Shanghai, China; and Taipei, Taiwan.
Detailed Description


505 Hamilton AvenueSuite 207Palo Alto, CA 94301United StatesFounded in 1996



Phone: 650-688-0818

Fax: 650-688-0815

vivocapital.com







Key Executives for Vivo Capital, LLC




Dr. Frank F. C. Kung Ph.D.


      	Senior Managing Partner
      


Age: 68
        







Mr. Hwachie Lee


      	Managing Director and Chief Investment Officer
      








Dr. Edgar G. Engleman M.D.


      	Managing Partner and Founding Member
      


Age: 71
        







Dr. Albert Cha M.D., Ph.D.


      	Managing Partner
      


Age: 45
        







Dr. Chen-Ming Yu M.D., M.B.A.


      	Managing Partner
      


Age: 43
        




Compensation as of Fiscal Year 2017. 

Vivo Capital, LLC Key Developments

Vivo Capital, LLC Presents at 12th Annual Private Equity & Venture Forum, Jul-12-2017
Jun 14 17
Vivo Capital, LLC Presents at 12th Annual Private Equity & Venture Forum, Jul-12-2017 . Venue: New York, New York, United States. Speakers: Frank F. C. Kung, Senior Managing Partner.


Vivo Capital, LLC Presents at Annual China Healthcare Investment Conference, Mar-28-2017 through Mar-30-2017
Mar 7 17
Vivo Capital, LLC Presents at Annual China Healthcare Investment Conference, Mar-28-2017 through Mar-30-2017. Venue: Shangri-La Pudong Hotel, Shanghai, China. Presentation Date & Speakers: Mar-29-2017, Edgar G. Engleman, Managing Partner and Founding Member. Mar-30-2017, Chen-Ming Yu, Managing Partner, Cyber Cao, Managing Director, Frank F. C. Kung, Senior Managing Partner, Michael Chang, Managing Director.


Vivo Capital, LLC Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017
Nov 21 16
Vivo Capital, LLC Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102, United States.


Similar Private Companies By Industry



Company Name
Region



 @Visory LLC United States 1 Road Partners LLC United States 11T Partners, LLC United States 123Jump.com, Inc. United States 1509225 Ontario, Inc. United States




Recent Private Companies Transactions



TypeDate
Target





Private Placement

			      July 18, 2017
			    
Menlo Therapeutics Inc.



Private Placement

			      June 28, 2017
			    
ZAI Lab Limited



Private Placement

			      June 26, 2017
			    
Selecta Biosciences, Inc.





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Vivo Capital, LLC, please visit vivocapital.com.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close

































Vivo Capital | healthcare focused investment firm




























 












LP ACCESS



   


 
 
 












Select Page



 
 








 









 
 
 




 
 


Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1.8 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and Greater China, and from its $100M PANDA fund into promising early-stage innovative healthcare companies.
Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising therapeutic products at all stages in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Beijing, Shanghai and Taipei.
With over 100 years of scientific expertise and operating experience in healthcare, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth. Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
 
 

Zai Lab Secures Series C Financing June 28, 2017WuXi Biologics prices HK IPO at top as investors seek growth business June 5, 2017Biohaven Announces Pricing of Initial Public Offering of Common Shares May 4, 2017Verona Pharma prices IPO at $13.50 April 26, 2017
 
 
 






 
 
 
 
 
 
 
 
 
 



















Vivo Capital | healthcare focused investment firm




























 












LP ACCESS



   


 
 
 












Select Page



 
 








 









 
 
 




 
 


Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1.8 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and Greater China, and from its $100M PANDA fund into promising early-stage innovative healthcare companies.
Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising therapeutic products at all stages in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Beijing, Shanghai and Taipei.
With over 100 years of scientific expertise and operating experience in healthcare, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth. Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
 
 

Zai Lab Secures Series C Financing June 28, 2017WuXi Biologics prices HK IPO at top as investors seek growth business June 5, 2017Biohaven Announces Pricing of Initial Public Offering of Common Shares May 4, 2017Verona Pharma prices IPO at $13.50 April 26, 2017
 
 
 






 
 
 
 
 
 
 
 
 
 



















Portfolio | Vivo Capital

























 












LP ACCESS



   


 
 
 












Select Page



 
 








 










 
 


PORTFOLIO
 
 
 
 



United States

Active
Aclaris Therapeutics
Advanced Accelerator Applications
Agile Therapeutics
AirXpanders
Akari Therapeutics
Ascendis Pharma
Biohaven Pharma
Aurinia
BioPharmX
CRISPR Therapeutics
Eiger
Foamix
Impel NeuroPharma
Kala Pharmaceuticals
KalVista Pharmaceuticals
Minerva Surgical
Nabriva Therapeutics
Outpost Medicine
REGENXBIO
Revance Therapeutics
Selecta Biosciences
Semnur Pharmaceuticals
SentreHEART
Sierra Oncology
Soleno Therapeutics
Strongbridge Biopharma
Surgical Specialties
Synapse BioMedical
Trevena
TRIA Beauty
Verona Pharma
Zai Lab
Exited


China
Early Stage (PANDA)
 
 
 





Aclaris Therapeutics (NASDAQ: ACRS) is a specialty pharmaceutical company focused on the development of novel dermatological therapies.



Advanced Accelerator Applications (NASDAQ: AAAP) is pioneering the field of Molecular Nuclear Medicine and aims to provide predictive, preventive and personalized tools and procedures that will radically transform healthcare management both for healthcare professionals and patients.



Agile Therapeutics (NASDAQ: AGRX) is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.



AirXpanders (ASX: AXP) is a medical device company that has developed the AeroForm tissue expander. AeroForm is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy.



Akari Therapeutics (NASDAQ: AKTX) is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.



Ascendis Pharma (NASDAQ: ASND) develops differentiated prodrug versions of high-value drugs. The company’s proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent lives.



Aurinia Pharmaceuticals is developing and delivering innovative products to patients suffering from debilitating diseases such as lupus nephritis (LN).



Biohaven Pharma (NASDAQ: BHVN) is a publicly held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.



BioPharmX (NYSE: BPMX) provides innovative healthcare products through its unique, patented platform technologies for pharmaceutical, over-the-counter (OTC), and supplement applications. 



CRISPR Therapeutics is a world leader in CRISPR Cas9 gene editing technology.



Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D.



Foamix (NASDAQ: FOMX) is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.



Impel NeuroPharma is using its Precision Olfactory Delivery (POD) nasal devices to develop therapies for diseases of the brain such as migraine and Alzheimer’s.



Kala is a company developing novel therapies to treat serious eye conditions.



KalVista Pharmaceuticals (NASDAQ: KALV) is creating a new generation of small molecule protease inhibitors.



Minerva Surgical is developing next-generation technology for treating excessive menstrual bleeding.



Nabriva (NASDAQ: NBRV) is an anti-infective company developing a novel therapy for Community Acquired Pneumonia.



Outpost Medicine is developing a novel therapy for overactive bladder and irritable bowel syndrome. 



REGENXBIO (NASDAQ: RGNX) is a gene therapy platform company that is leveraging its proprietary NAV® Technology to advance the development of life-changing adeno-associated viral (AAV) treatments for lysosomal storage disorders, ocular diseases, and other unmet clinical needs.



Revance Therapeutics (NASDAQ: RVNC) is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology.



Selecta is a clinical-stage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system.



Semnur Pharmaceuticals is a pharmaceutical company developing an injectable product for the treatment of lower back pain.



SentreHEART is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications.



Sierra Oncology (NASDAQ: SRRA) is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.



Soleno Therapeutics  (NASDAQ: SLNO) is developing a novel treatment for patients with Prader-Willi syndrome (PWS).



Strongbridge Biopharma focuses on rare diseases has resulted in a portfolio of innovative treatments for rare endocrine conditions.



Surgical Specialties is a medical device company that is marketing surgical products on a worldwide basis.



Synapse BioMedical is a medical device company developing neurostimulation products. The company’s products have been approved by the FDA for patients with spinal cord injury and amyotrophic lateral sclerosis.



Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines.



TRIA Beauty is a leader in light-based therapeutic beauty systems that incorporate clinically-proven aesthetic technologies for at-home personal care regimens.



Verona Pharma (LSE AIM:VRP.L) is focused on developing new drugs for a range of respiratory diseases.



Zai Lab is a Shanghai-based biopharmaceutical company. Our globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing our own therapeutics for patients worldwide.

 
 
 
 
 
 
 
 
 
 
 
 



















Portfolio | Vivo Capital

























 












LP ACCESS



   


 
 
 












Select Page



 
 








 










 
 


PORTFOLIO
 
 
 
 



United States

Active
Aclaris Therapeutics
Advanced Accelerator Applications
Agile Therapeutics
AirXpanders
Akari Therapeutics
Ascendis Pharma
Biohaven Pharma
Aurinia
BioPharmX
CRISPR Therapeutics
Eiger
Foamix
Impel NeuroPharma
Kala Pharmaceuticals
KalVista Pharmaceuticals
Minerva Surgical
Nabriva Therapeutics
Outpost Medicine
REGENXBIO
Revance Therapeutics
Selecta Biosciences
Semnur Pharmaceuticals
SentreHEART
Sierra Oncology
Soleno Therapeutics
Strongbridge Biopharma
Surgical Specialties
Synapse BioMedical
Trevena
TRIA Beauty
Verona Pharma
Zai Lab
Exited


China
Early Stage (PANDA)
 
 
 





Aclaris Therapeutics (NASDAQ: ACRS) is a specialty pharmaceutical company focused on the development of novel dermatological therapies.



Advanced Accelerator Applications (NASDAQ: AAAP) is pioneering the field of Molecular Nuclear Medicine and aims to provide predictive, preventive and personalized tools and procedures that will radically transform healthcare management both for healthcare professionals and patients.



Agile Therapeutics (NASDAQ: AGRX) is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.



AirXpanders (ASX: AXP) is a medical device company that has developed the AeroForm tissue expander. AeroForm is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy.



Akari Therapeutics (NASDAQ: AKTX) is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.



Ascendis Pharma (NASDAQ: ASND) develops differentiated prodrug versions of high-value drugs. The company’s proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent lives.



Aurinia Pharmaceuticals is developing and delivering innovative products to patients suffering from debilitating diseases such as lupus nephritis (LN).



Biohaven Pharma (NASDAQ: BHVN) is a publicly held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.



BioPharmX (NYSE: BPMX) provides innovative healthcare products through its unique, patented platform technologies for pharmaceutical, over-the-counter (OTC), and supplement applications. 



CRISPR Therapeutics is a world leader in CRISPR Cas9 gene editing technology.



Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D.



Foamix (NASDAQ: FOMX) is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.



Impel NeuroPharma is using its Precision Olfactory Delivery (POD) nasal devices to develop therapies for diseases of the brain such as migraine and Alzheimer’s.



Kala is a company developing novel therapies to treat serious eye conditions.



KalVista Pharmaceuticals (NASDAQ: KALV) is creating a new generation of small molecule protease inhibitors.



Minerva Surgical is developing next-generation technology for treating excessive menstrual bleeding.



Nabriva (NASDAQ: NBRV) is an anti-infective company developing a novel therapy for Community Acquired Pneumonia.



Outpost Medicine is developing a novel therapy for overactive bladder and irritable bowel syndrome. 



REGENXBIO (NASDAQ: RGNX) is a gene therapy platform company that is leveraging its proprietary NAV® Technology to advance the development of life-changing adeno-associated viral (AAV) treatments for lysosomal storage disorders, ocular diseases, and other unmet clinical needs.



Revance Therapeutics (NASDAQ: RVNC) is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology.



Selecta is a clinical-stage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system.



Semnur Pharmaceuticals is a pharmaceutical company developing an injectable product for the treatment of lower back pain.



SentreHEART is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications.



Sierra Oncology (NASDAQ: SRRA) is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.



Soleno Therapeutics  (NASDAQ: SLNO) is developing a novel treatment for patients with Prader-Willi syndrome (PWS).



Strongbridge Biopharma focuses on rare diseases has resulted in a portfolio of innovative treatments for rare endocrine conditions.



Surgical Specialties is a medical device company that is marketing surgical products on a worldwide basis.



Synapse BioMedical is a medical device company developing neurostimulation products. The company’s products have been approved by the FDA for patients with spinal cord injury and amyotrophic lateral sclerosis.



Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines.



TRIA Beauty is a leader in light-based therapeutic beauty systems that incorporate clinically-proven aesthetic technologies for at-home personal care regimens.



Verona Pharma (LSE AIM:VRP.L) is focused on developing new drugs for a range of respiratory diseases.



Zai Lab is a Shanghai-based biopharmaceutical company. Our globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing our own therapeutics for patients worldwide.

 
 
 
 
 
 
 
 
 
 
 
 



















Team | Vivo Capital

























 












LP ACCESS



   


 
 
 












Select Page



 
 








 










 
 


TEAM
 
 
 
 



Frank Kung, Ph.D., M.B.A.
Albert Cha, M.D., Ph.D.
Edgar G. Engleman, M.D.
Shan Fu, M.A.
Chen Yu, M.D., M.B.A.
Mahendra G. Shah, Ph.D.
Hwachie Lee
Lawrence Wang, M.D., M.B.A.
Gaurav Aggarwal, M.D.
Michael Chang, M.B.A.
Joseph Siletto, M.B.A.
Daisy Xu, M.S.
Dan Dan Dong, Ph.D.
Qi Zhu, M.A.
Nina Feng, M.B.A., CFA
Andrew D. Goldberg, M.D.
Kevin Dai, Pharm.D, BCOP
Daniel Qin
Nathan Dau, J.D., MBA
Ethan Zhao
Sue Shao, M.S.
Lingfei Zhao, M.S.
Waika Cheng, M.B.A.
Yixuan Li, M.S.
Jo Shen, Ph.D.
Yuh-geng Tsay, Ph.D.
Ronghuan Lin, M.A., EMBA
 
 
 




Frank Kung
Managing Partner
 
 


Albert Cha
Managing Partner
 
 


Edgar G. Engleman
Managing Partner
 
 
 



Shan Fu
Managing Partner
 
 


Chen Yu
Managing Partner
 
 


Mahendra G. Shah
Managing Director
 
 
 



Hwachie Lee
Managing Director & CIO China
 
 


Lawrence Wang
Managing Director
 
 


Gaurav Aggarwal
Managing Director
 
 
 



Michael Chang
Managing Director
 
 


Joseph Siletto
Managing Director
 
 


Daisy Xu
General Director
 
 
 



Dan Dan Dong
Principal
 
 


Qi Zhu
Principal
 
 


Nina Feng
Principal
 
 
 



Andrew D. Goldberg
Principal
 
 


Kevin Dai
Principal
 
 


Daniel Qin
Associate
 
 
 



Nathan Dau
Associate
 
 


Ethan Zhao
Associate
 
 


Sue Shao
Associate
 
 
 



Lingfei Zhao
Analyst
 
 


Waika Cheng
Analyst
 
 


Yixuan Li
Analyst
 
 
 



Jo Shen
Venture Partner
 
 


Yuh-geng Tsay
Venture Partner
 
 


Ronghuan Lin
Advisor
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 

































 



 Vivo Capital and ZQ Capital Limited enter into an Agreement to Acquire Angiotech Pharmaceuticals 
         










    










 













 











 



















Vivo Capital and ZQ Capital Limited enter into an Agreement to Acquire Angiotech Pharmaceuticals
        																																
              











 News provided by
Vivo Capital  
Dec 19, 2016, 06:00 ET









 Share this article




























































PALO ALTO, Calif. and VANCOUVER, British Columbia, Dec. 19, 2016 /PRNewswire/ -- Angiotech Pharmaceuticals (Canada) today announced that it has entered into a definitive agreement to be acquired by a group of investors led by Vivo Capital LLC, a leading healthcare focused investment firm, and ZQ Capital Limited, a leading China-based investment and advisory firm.  The investment syndicate also includes GSO Capital Partners LP, China Orient Asset Management (International) Holding Limited and Fung Shing Investments Ltd.  Pursuant to the agreement, the investment syndicate will acquire 100% of the shares of Angiotech.  In addition, business development companies managed by affiliates of FS Investments and sub-advised by an affiliate of GSO Capital Partners LP (GSO, a division of The Blackstone Group), provided senior secured financing into the transaction.  The terms of the transaction were not disclosed.  The closing of the transaction is expected to occur during the first quarter of 2017.








Angiotech is a diversified medical device manufacturer of branded, private label and OEM products with more than 2,000 employees worldwide, manufacturing facilities in England, Puerto Rico, Mexico and Germany and customers in over 80 countries worldwide.  
Chen Yu, Managing Partner of Vivo Capital, commented, "We are excited by the opportunity to work with the management team, employees and customers of Angiotech Pharmaceuticals. The Company is well positioned for continued sales growth in their core markets of needles, sutures and surgical knives. We look forward to working with them to selectively expand the product offerings leveraging the multi-channel strategy used by Angiotech, while driving strong geographic growth in key markets including China and other parts of Asia."
Simon Shen, Chairman of ZQ Capital, commented, "We believe that Angiotech fits perfectly with our growth strategy and are excited to welcome the Company and its strong management team and employees to our portfolio.  We are honored to have the opportunity to partner with the Company to further enhance its comprehensive product offerings and markets and to expand its influence and benefits to millions of patients worldwide, including in China."
"The key shareholders in Angiotech Pharmaceuticals believe this is an excellent time to transition to new ownership and we are confident that the syndicate led by Vivo Capital and ZQ Capital Limited will continue the strong momentum already established," commented Jeff Goldberg, Co-Chairman of the Board of Angiotech Pharmaceuticals.  "The Company has made significant progress under this shareholder group including enhancing the management team, launching new products and line extensions, while streamlining operations."
John Barr, CEO of Angiotech, commented, "I would first like to thank our customers for their continued support of Angiotech. We remain committed to continuing to improve our ability to service those customers. Our employees have worked hard and through significant change over the past few years. We acknowledge their continued commitment to the mission of Angiotech Pharmaceuticals that centers on our customers. I want to thank our shareholders and Board for their investment, long term support and strong guidance in Angiotech and the critical role they played in our success. The management team and I are excited to work with our new owners on a seamless transition and to further accelerate our growth while continuing to invest in improved quality and service for all our customers."
O'Melveny & Myers LLP is acting as legal advisor to the investment syndicate and Paul Hastings LLP and Magstone Law acted as legal advisors to ZQ Capital. Piper Jaffray & Co is acting as financial advisor and Irell & Manella LLP as legal advisor, respectively, to Angiotech.
About Vivo Capital
Vivo Capital is a global healthcare focused investment firm formed in 1996 with over $1.8 billion under management.  Vivo Capital has offices in Palo Alto, California, Beijing, Shanghai and Taipei.  Vivo's current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
More information can be found at www.vivocapital.com.
About ZQ Capital Limited
ZQ Capital is an investment and advisory firm that specializes in identifying, investing in, and working together with global companies to realize their growth potential in the Chinese market.  Utilizing its deep local knowledge of China as well as extensive relationships with financial institutions and leading entrepreneurs across numerous industries in Asia, ZQ Capital is focused on partnering with successful global brands and leveraging its relationships in and knowledge of China to bring added value to its partners.
About China Orient Asset Management (International) Holding Limited
China Orient Asset Management (International) Holding Limited is headquartered in Hong Kong, and is a wholly-owned subsidiary of China Orient Asset Management Group Company.  COAMI is the Group Company's primary overseas platform. As of 31 December 2015, COAMI has assets over HKD 52bn. The key businesses of COAMI include investment, corporate finance advisory, non-performing asset acquisitions and asset management.
About Fung Shing Investment Limited
Fung Shing Investment Limited is an investment company that invests in various sectors, including but not limited to media, telecom, healthcare, real estate and financial institutions.
About Angiotech 
Angiotech Pharmaceuticals has developed and manufactured branded, private label, and OEM surgical instruments for over 40 years. The Company offers one of the most comprehensive portfolios of blades and sutures available, including innovative products such as the Quill Knotless Tissue-Closure Device. Headquartered in Vancouver, CA, Angiotech devotes itself to exceeding the needs of the specialty surgery market, having trusted partnerships within dental, ophthalmic, plastic surgery, dermatology, orthopedics, urology, microsurgery, veterinary and trauma specialties. The key shareholders in Angiotech include affiliates of Blue Mountain Capital LLC, Courage Capital Management LLC and Cetus Capital LLC.
 
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vivo-capital-and-zq-capital-limited-enter-into-an-agreement-to-acquire-angiotech-pharmaceuticals-300380542.html
SOURCE Vivo Capital
 Related Links

http://www.vivoventures.com



 












Mar 21, 2017, 06:00 ET
Preview: Angiotech Pharmaceuticals Completes Sale to Investor Syndicate Led by Vivo Capital and ZQ Capital













Jun 13, 2016, 08:00 ET
Preview: Vivo Capital Closes First Healthcare Venture Capital Focused Fund at Over $100 Million






My News


  Release contains wide tables.	  View fullscreen.





 Also from this source




 

Mar 21, 2017, 06:00 ET
                                  				                                                                                     
                              Angiotech Pharmaceuticals Completes Sale to Investor Syndicate...






 Explore
 More news releases in similar topics

  Banking & Financial Services
  Health Care & Hospitals
  Medical Equipment
Acquisitions, Mergers and Takeovers








 You just read:
Vivo Capital and ZQ Capital Limited enter into an Agreement to Acquire Angiotech Pharmaceuticals


 News provided by
Vivo Capital  
Dec 19, 2016, 06:00 ET








 Share this article









































 











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

















Search











Searching for your content...









Advanced Search












































 




Vivo Capital LLC: Company Profile - Bloomberg



































































  









Feedback









































vivo capital llc
Private Company









Company Profile
Sector: Financials
Industry: Asset Management
Sub-Industry: Investment Companies
Vivo Capital LLC operates as an investment firm. The Company invests in healthcare, therapeutics, pharmaceutical, and other sectors. Vivo Capital serves clients worldwide.




Corporate Information
Address:

505 Hamilton Avenue
Suite 207
Palo Alto, CA 94301
United States


Phone:
1-650-688-0818


Fax:
1-650-688-0815


Web url:
www.vivocapital.com





Board Members




Managing Dir/Venture Partner
Company


Mahendra Shah
Vivo Capital LLC


























From The Web











Key Executives


Frank F C Kung


Managing Partner




Albert Cha


Managing Partner




Edgar G Engleman "Ed"


Partner/Co-Founder




Fu Shan


Managing Partner




Chen-Ming Yu


Managing Partner




Mahendra G Shah


Managing Dir/Venture Partner




Hwachie Lee


Managing Director/CIO:China




Gaurav Aggarwal


Managing Director




Cyber Cao


Managing Director




Lawrence Wang


Managing Director




Joseph Siletto


Managing Director




Tsay Yuh-Geng


Venture Partner




Jo Shen


Venture Partner




Michael Chang


Principal




Xu Daisy


Principal




Dan Dan Dong


Principal




Qi Zhu


Principal




Nina Feng


Principal



Show More


Show Less






Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data





































Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version

























Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.





Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft




















VIVO CAPITAL, LLC Institutional Portfolio - NASDAQ.com






























































Hot Topics:
ETFs |
Smart Portfolio |
Currencies |
Online Broker Center















Search






















Home > 
	Quotes > 
	Ownership & Insider Trades > 
    Institutional Portfolio






VIVO CAPITAL, LLC






505 HAMILTON AVENUE, SUITE 207, PALO ALTO,  California, 94301, (650) 688-0818


Report Date: 03/31/2017

Position Statistics


Total Positions
25


New Positions
1


Increased Positions
3


Decreased Positions
4


Positions with Activity
7


Sold Out Positions
2


Total Mkt Value (in $ millions)
332



Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission.



Sector Weighting



Energy



Basic Materials



Industrials



Consumer Cyclicals



Consumer Non-Cyclicals



Financials



Healthcare
100%


Technology



Telecommunication Services



Utilities










Total Positions




New




Increased




Decreased




Activity




Sold Out






25 Positions as of 03/31/2017


Company

Class

Value of Shares ($1,000s) ▼

Change in Value ($1,000s)

Change (%)

Shares Held



ACLARIS THERAPEUTICS INC
COM
83,413
-12,402
(12.94)
2,858,569


ASCENDIS PHARMA A S
SPONSORED ADR
49,577

New
1,766,832


NABRIVA THERAPEUTICS PLC
SHS
44,157

New
4,021,559


CODEXIS INC
COM
29,386

New
5,294,825


ADVANCED ACCELERATOR APPLIC
SPONSORED ADS
20,483
1,185
6.14
483,786


STRONGBRIDGE BIOPHARMA PLC
SHS USD
19,650

New
3,000,000


AIMMUNE THERAPEUTICS INC
COM
16,351

New
763,009


EIGER BIOPHARMACEUTICALS INC
COM
15,905

New
1,787,091


SOLENO THERAPEUTICS INC
COM
8,082
3,981
97.07
14,695,264


AGILE THERAPEUTICS INC
COM
6,964

New
1,513,975


TREVENA INC
COM
4,579

New
1,728,000


BIOPHARMX CORP
COM
4,498

New
12,814,286


FOAMIX PHARMACEUTICALS LTD
SHS
4,403

New
855,000


AURINIA PHARMACEUTICALS INC
COM
3,786
3,786
New
600,000


SIERRA ONCOLOGY INC
COM
3,535

New
2,438,270


DYNAVAX TECHNOLOGIES CORP
COM NEW
3,328

New
359,828


REGENXBIO INC
COM
3,083
-6,346
(67.31)
164,403


CRISPR THERAPEUTICS AG
NAMEN AKT
2,631

New
148,878


AKARI THERAPEUTICS PLC
SPONSORED ADR
2,375

New
527,842


KALVISTA PHARMACEUTICALS INC
COM
2,213

New
300,325




<< first< previous12next >last >>








Latest News Headlines




                            Sprint proposes merger with Charter Communications - WSJ
                        



	                     7:53PM ET  - Reuters
	                




                            Union cheers as trucks kept out of U.S. self-driving legislation
                        



	                     6:57PM ET  - Reuters
	                




                            RPT-Hundreds of U.S. counties at risk for no Obamacare insurer in 2018
                        



	                     6:48PM ET  - Reuters
	                




                            Wells Fargo faces angry questions after new sales abuses uncovered
                        



	                     6:41PM ET  - Reuters
	                




                            U.S. regulators weigh future of appeal in MetLife case
                        



	                     6:17PM ET  - Reuters
	                





View All Latest Headlines



































CLOSEX

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.






Update

Clear List







CLOSEX
Customize your NASDAQ.com experience
Background Color Selector

Select the background color of your choice:





 Black
							





 Slate Gray
							






 Light Gray
							





 Gray Blue
							






Quote Search

Select a default target page for your quote search:



						 Real-Time

						 After Hours

						 Pre-Market
 News
					


						 Flash Quote

						 Summary Quote

						 Interactive Charts

						 Default Setting




					Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
					If, at any time, you are interested in reverting to our default settings, please select Default Setting above.
					
					If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.
				





CLOSEX
Please confirm your selection:

					You have selected to change your default setting for the Quote Search. This will now be your default target page;
					unless you change your configuration again, or you delete your
					cookies. Are you sure you want to change your settings?


YES
NO













CLOSEX


Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.





CLOSEX


































